ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

被引：217

作者：

Cang, Shundong ^{[1
]}

Iragavarapu, Chaitanya ^{[2
,3
]}

Savooji, John ^{[2
,3
]}

Song, Yongping ^{[4
,5
]}

Liu, Delong ^{[4
,5
]}

机构：

[1] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou 450052, Peoples R China

[2] Westchester Cty Med Ctr, Dept Med, Valhalla, NY 10595 USA

[3] New York Med Coll, Valhalla, NY 10595 USA

[4] Zhengzhou Univ, Henan Canc Hosp, Zhengzhou 450052, Peoples R China

[5] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450052, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2015年 / 8卷

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-VIVO EFFICACY; BISPECIFIC ANTI-CD30/CD16A ANTIBODY; ACUTE MYELOID-LEUKEMIA; BH3 MIMETIC ABT-263; FAMILY PROTEINS; CELL-DEATH; HEMATOLOGICAL MALIGNANCIES; NUCLEAR EXPORT;

D O I：

10.1186/s13045-015-0224-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 ( venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.

引用

页数：8

共 50 条

[1] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang
Chaitanya Iragavarapu
John Savooji
Yongping Song
Delong Liu
Journal of Hematology & Oncology, 8
[2] Quantitative assessment of BCL-2: BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199)
Jin, Sha
Tapang, Paul
Osterling, Donald J.
Gao, Wenqing
Albert, Daniel H.
Souers, Andrew J.
Leverson, Joel D.
Phillips, Darren C.
Chen, Jun
CANCER RESEARCH, 2015, 75
[3] ABT-199: Taking Dead Aim at BCL-2
Davids, Matthew S.
Letai, Anthony
CANCER CELL, 2013, 23 (02) : 139 - 141
[4] Correlative biomarkers of clinical activity of the BCL-2 inhibitor, venetoclax (ABT-199/GDC-0199), in acute myeloid leukemia patients
Popovic, Relja
Daver, Naval
Ruvolo, Vivian
Chen, Ken
Wang, Zixing
Huang, Xin
Mabry, Mack
Potluri, Jalaja
McKeegan, Evelyn
Konopleva, Marina
Chyla, Brenda J.
CANCER RESEARCH, 2016, 76
[5] The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199
Choo, Edna F.
Boggs, Jason
Zhu, Chunqiang
Lubach, Joseph W.
Catron, Nathaniel D.
Jenkins, Gary
Souers, Andrew J.
Voorman, Richard
DRUG METABOLISM AND DISPOSITION, 2014, 42 (02) : 207 - 212
[6] The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
Weller, Sandra
Toenniessen, Astrid
Schaefer, Benjamin
Beigl, Tobias
Muenchow, Alina
Bopple, Kathrin
Hofmann, Ute
Gillissen, Bernhard F.
Aulitzky, Walter E.
Kopp, Hans-Georg
Essmann, Frank
CELL DEATH DISCOVERY, 2022, 8 (01)
[7] The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
Sandra Weller
Astrid Toennießen
Benjamin Schaefer
Tobias Beigl
Alina Muenchow
Kathrin Böpple
Ute Hofmann
Bernhard F. Gillissen
Walter E. Aulitzky
Hans-Georg Kopp
Frank Essmann
Cell Death Discovery, 8
[8] Remarkable early clinical activity with the Bcl-2 selective inhibitor ABT-199: Proving the concept.
Humerickhouse, Rod
CANCER RESEARCH, 2013, 73 (08)
[9] Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma
Matulis, Shannon
Nooka, Ajay K.
Von Hollen, Hayley
Kaufman, Jonathan L.
Lonial, Sagar
Boise, Lawrence H.
BLOOD, 2014, 124 (21)
[10] The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia
Itchaki, Gilad
Brown, Jennifer R.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (05) : 270 - 287

← 1 2 3 4 5 →